PMID- 18441292 OWN - NLM STAT- MEDLINE DCOM- 20080721 LR - 20240317 IS - 1549-5485 (Electronic) IS - 1072-0502 (Print) IS - 1072-0502 (Linking) VI - 15 IP - 5 DP - 2008 May TI - Proteasome inhibition enhances the induction and impairs the maintenance of late-phase long-term potentiation. PG - 335-47 LID - 10.1101/lm.984508 [doi] AB - Protein degradation by the ubiquitin-proteasome pathway plays important roles in synaptic plasticity, but the molecular mechanisms by which proteolysis regulates synaptic strength are not well understood. We investigated the role of the proteasome in hippocampal late-phase long-term potentiation (L-LTP), a model for enduring synaptic plasticity. We show here that inhibition of the proteasome enhances the induction of L-LTP, but inhibits its maintenance. Proteasome inhibitor-mediated enhancement of the early part of L-LTP requires activation of NMDA receptors and the cAMP-dependent protein kinase. Augmentation of L-LTP induction by proteasome inhibition is blocked by a protein synthesis inhibitor anisomycin and is sensitive to the drug rapamycin. Our findings indicate that proteasome inhibition increases the induction of L-LTP by stabilizing locally translated proteins in dendrites. In addition, our data show that inhibition of the proteasome blocks transcription of brain-derived neurotrophic factor (BDNF), which is a cAMP-responsive element-binding protein (CREB)-inducible gene. Furthermore, our results demonstrate that the proteasome inhibitors block degradation of ATF4, a CREB repressor. Thus, proteasome inhibition appears to hinder CREB-mediated transcription. Our results indicate that blockade of proteasome activity obstructs the maintenance of L-LTP by interfering with transcription as well as translation required to sustain L-LTP. Thus, proteasome-mediated proteolysis has different roles during the induction and the maintenance of L-LTP. FAU - Dong, Chenghai AU - Dong C AD - Department of Neurobiology and Anatomy, Wake Forest University Health Sciences, Winston-Salem, North Carolina 27157, USA. FAU - Upadhya, Sudarshan C AU - Upadhya SC FAU - Ding, Lan AU - Ding L FAU - Smith, Thuy K AU - Smith TK FAU - Hegde, Ashok N AU - Hegde AN LA - eng GR - R01 MH060225/MH/NIMH NIH HHS/United States GR - MH060225/MH/NIMH NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20080425 PL - United States TA - Learn Mem JT - Learning & memory (Cold Spring Harbor, N.Y.) JID - 9435678 RN - 0 (Brain-Derived Neurotrophic Factor) RN - 0 (Cyclic AMP Response Element-Binding Protein) RN - 0 (Proteasome Inhibitors) RN - 0 (Protein Synthesis Inhibitors) RN - 0 (RNA, Messenger) RN - 0 (Receptors, N-Methyl-D-Aspartate) RN - 0 (Ubiquitin) RN - 6C74YM2NGI (Anisomycin) RN - EC 2.7.11.11 (Cyclic AMP-Dependent Protein Kinases) RN - EC 3.4.- (Peptide Hydrolases) SB - IM MH - Animals MH - Anisomycin/administration & dosage/*pharmacology MH - Brain-Derived Neurotrophic Factor/genetics MH - Cyclic AMP Response Element-Binding Protein/genetics MH - Cyclic AMP-Dependent Protein Kinases/metabolism MH - Dendrites/metabolism MH - Hippocampus/drug effects MH - Long-Term Potentiation/*drug effects MH - Mice MH - Neuronal Plasticity/drug effects MH - Peptide Hydrolases/pharmacology MH - *Proteasome Inhibitors MH - Protein Biosynthesis/drug effects/genetics MH - Protein Synthesis Inhibitors/administration & dosage/*pharmacology MH - RNA, Messenger/drug effects MH - Receptors, N-Methyl-D-Aspartate/drug effects MH - Synapses/drug effects MH - Transcriptional Activation/drug effects/genetics MH - Ubiquitin/*drug effects PMC - PMC2364605 EDAT- 2008/04/29 09:00 MHDA- 2008/07/22 09:00 PMCR- 2009/05/01 CRDT- 2008/04/29 09:00 PHST- 2008/04/29 09:00 [pubmed] PHST- 2008/07/22 09:00 [medline] PHST- 2008/04/29 09:00 [entrez] PHST- 2009/05/01 00:00 [pmc-release] AID - 15/5/335 [pii] AID - 10.1101/lm.984508 [doi] PST - epublish SO - Learn Mem. 2008 Apr 25;15(5):335-47. doi: 10.1101/lm.984508. Print 2008 May.